Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Infliximab Stories

2014-03-27 08:33:57

DUBLIN, Mar. 27, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/x6dsmh/therapeutic_class) has announced the addition of the "Therapeutic Class Overview : Emergence of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) With three products and eight players already in market - Japan biosimilar market will enter new phase...

2014-03-25 20:22:11

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q29sqz/global_and ) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Report" [http://www.researchandmarkets.com/research/q29sqz/global_and ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Currently, monoclonal antibody agents have been successfully used in the treatment...

2014-03-21 23:03:40

ResearchMoz.us include new market research report "PharmaPoint: Crohns Disease - China Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. Browse full report - http://www.researchmoz.us/pharmapoint-crohns-disease-china-drug-forecast-and-market-analysis-to-2022-report.html. Albany, NY (PRWEB) March 21, 2014 The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the...

2014-03-20 08:29:06

NORTH CHICAGO, Ill., March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need. Currently there are no approved treatments for fingernail psoriasis. "Since treatment options are limited, we welcome research that evaluates new options for patients suffering...

2014-02-19 12:28:56

NEW YORK, LONDON, BERLIN, PARIS, February 19, 2014 /PRNewswire/ -- Reportstack has announced a newly published market intelligence report on Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 [http://www.reportstack.com/product/150599/pharmapoint-ulcerative-colitis-global-drug-forecast-and-market-analysis-to-2022.html ] . The global ulcerative colitis (UC) market value will increase steadily over the coming years, growing from almost $4.2 billion in 2012...

2014-01-16 16:24:09

AUSTIN, Texas, Jan. 16, 2014 /PRNewswire/ -- XBiotech announced today that it has launched a Phase II study to treat a rare but debilitating disorder, Pyoderma Gangrenosum (PG). This study is based on efficacy seen with anti-IL-1 therapeutic antibody in previous dermatological clinical studies such as psoriasis and acne. PG is expected to be considered an "orphan indication" by the FDA, facilitating expedited clinical development to market. Dr. Armand Cognetta, lead clinical...

2013-12-25 23:01:37

ResearchMoz.us include new market research report " Global and China Monoclonal Antibody Industry Report, 2013 - 2017 " to its huge collection of research reports. Browse full report - http://www.researchmoz.us/global-and-china-monoclonal-antibody-industry-report-2013-2017-report.html Albany, NY (PRWEB) December 25, 2013 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the...

2013-12-24 23:20:33

ChinaMarketResearchReports.com adds “Global and China Monoclonal Antibody Industry Report, 2013-2017” latest report to its store. Dallas, TX (PRWEB) December 24, 2013 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of...

2013-12-16 08:27:16

Oral 5-Aminosalicylates Will Remain the Preferred Treatment Regimen for Early Lines of Therapy, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through an examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has experienced steady growth among recently treated Crohn's disease (CD)...

2013-12-16 08:26:04

However, Novel Agents Will Face Reimbursement and Uptake Challenges if Robust Superiority over Anti-TNFs is Lacking, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when considering the most important attributes for prescribing emerging therapies for Crohn's disease (CD) and ulcerative colitis (UC),...